How do biotechs build a defensible data moat?
Costs keep doubling while approvals don't, how do I turn continuous monitoring into portfolio decisions and a moat that actually compounds?
~90% of drugs fail, and the costly mistake is stopping too late - €10M at lab stage versus €1B at human. In a custom build on the PharosBio Clinical Trial Retriever API, we connected early-stop monitoring to portfolio strategy: where to cut and where to redirect budget, the preclinical entry wedge, and the commercial case in a market growing from ~$31.7B to ~$64B by 2030.
Who this is for: Executives, business-development, and strategy leaders shaping portfolio direction and building a defensible data moat.
- of drugs fail - usually by stopping too late
- ~90%
- cost of failing at lab vs human stage
- €10M → €1B
- AI drug-discovery market by 2030 (~15% CAGR)
- $31.7B → $64B
- API also available as a skill in Hydra
- custom build
of drugs fail - usually by stopping too late
cost of failing at lab vs human stage
AI drug-discovery market by 2030 (~15% CAGR)
API also available as a skill in Hydra
Why monitoring alone doesn't move the needle
The backdrop is Eroom's law: large-pharma R&D spend has roughly doubled over ten years, yet the industry still delivers around fifty drugs a year at a success rate below ten percent. Costs keep doubling; approvals don't. Against that headwind, simply tracking the landscape isn't enough.
The strategic questions are what to do with the monitoring: where is the unaddressed need, which direction is defensible, and how does today's data make tomorrow's position stronger rather than just better-informed? For a company raising capital, that defensibility is the entire story, investors price a compounding asset very differently from one that merely runs studies.
What teams in this space search for
- How do biotechs build a defensible data moat?
- How do I find white space in oncology?
- Why does drug R&D keep getting more expensive (Eroom's law)?
How we built it
A custom strategy build on the PharosBio Clinical Trial Retriever API - the same engine behind the monitoring work. It links early-stop signals (publications, safety, clinical outcomes, PK/PD, IC50) to budget decisions, and frames the commercial case: where to redirect spend, the preclinical entry wedge, and AI-pharma deal economics.
How the pipeline works
Strategy starts where monitoring leaves off. The same live board that flags a failing asset also says where to redirect: cut losses on the asset whose probability is sliding, and move that budget to the one with momentum. On the example board the recommendation is explicit - redirect ~€2M from a stalling diabetes asset to accelerate an oncology asset with strong week-12 data.
We tie that to the commercial picture. The entry wedge is preclinical - ~1.9 million animal studies a year, largely untouched by incumbents - monetised first as SaaS, then per asset. The market is moving from ~$31.7B to ~$64B by 2030 (≈15% CAGR), and AI-pharma licensing deals average ~$37M upfront and ~$1.6B total, about $8.5M per asset.
What it found
The strategic payoff is fail-fast, scale-faster: cutting a losing programme before Phase 1 can save tens of millions, while the freed budget accelerates the assets most likely to succeed. The earlier the stop, the larger the saving - the cost curve runs €10M (lab) → €440M (animal) → €1,000M (human).
Because every decision is evidenced and every result captured, the proprietary picture compounds: each analysis starts smarter than the last - the part a competitor without your data and history cannot easily copy.
What we learned
Monitoring alone is informative; strategy is what you do with it. Connecting early-stop signals to budget decisions, and to a clear commercial wedge, is what turns intelligence into ROI.
Like the monitoring work, this was a custom build on the PharosBio Clinical Trial Retriever API, available as a skill in Hydra. The same engine that scores trials can pressure-test where a portfolio is exposed and where the white space is.
A monitored portfolio, refreshed as new evidence lands. Each asset carries a moving success probability; click an alerted asset to see exactly what changed and what to do about it.
| Asset | Indication | Phase | Success prob. | Status |
|---|---|---|---|---|
| Drug A | T2 Diabetes | Preclinical | 32% → 18% | ALERT |
| Drug B | NASH | Preclinical | 71% → 73% | Stable |
| Drug C | Alzheimer's | Preclinical | 45% → 38% | Review |
| Drug D | Oncology | Preclinical | 82% → 85% | PRIORITIZE |
| Drug E | Parkinson's | On Hold | 12% | Stopped |
Drug A - Immediate review recommended
Probability dropped 14 points in 48 hours
What changed
- Competitor failure: A similar GLP-1/GIP dual agonist failed Phase 2 (liver-enzyme elevation in 23% of patients).
- New publication: A JAMA study links GPR40 agonism to hepatotoxicity in patients with pre-existing NAFLD.
- Your data: Week-8 preclinical results show 15% ALT elevation (borderline).
Recommended actions
- Run an extended 12-week tox study with liver monitoring (~€50K, 3 months)
- Test in a NAFLD disease model (~€30K, 6 weeks)
- If signals persist: stop before Phase 1 (save ~€45M)
Click Drug A or Drug D to see why the probability moved.
The cost of stopping too late
~90% of drugs fail. The issue is rarely failure itself - it is stopping too late, after the most expensive studies are already paid for.
competitor Phase 2 readouts
class hepatotoxicity, AE overlap
HR, ORR, PFS by subtype
exposure, potency, model relevance
Agent links them
Call the stop - or the acceleration - earlier
Connect a programme’s own PK/PD and IC50 to the literature and clinical record, and a redirect that would have surfaced after animal studies can surface before them.
The same monitoring that cuts losses early is also the commercial wedge: enter at preclinical, where incumbents are thin, then monetise per asset.
$31.7B → $64B
AI drug-discovery market, 2025 → 2030 (≈15% CAGR)
$37M / $1.6B
average AI-pharma deal: upfront / total value (~$8.5M per asset)
1.9M / yr
animal studies - the preclinical wedge incumbents largely skip
One API, many workflows
This was a custom build for a partner, powered by the PharosBio Clinical Trial Retriever API - which fetches clinical endpoints and scores drug similarity by target and mechanism of action. The same API can be repointed at:
- Safety scoring for combinations
- Extrapolating clinical outcome from in vivo data
- Portfolio monitoring
- Drug repurposing
It is also available as a skill inside Hydra
What you get
- A fail-fast / scale-faster rule: cut losing assets early, redirect budget to winners
- Early-stop savings quantified against the €10M → €1B cost curve
- A commercial case: preclinical wedge, market growth, and per-asset deal economics
- A compounding, evidenced picture that a competitor can't easily replicate
Data sources used
- ClinicalTrials.gov & published outcomes (landscape)
- cBioPortal / TCGA (biomarker & subtype context)
- Your proprietary data (compounded over time)
Figures reflect analyses PharosBio ran on public datasets and public benchmarks. Named competitors, collaborators, and logos are withheld at this stage; the methods and results shown are real and repointable to your own target.
Sources & methods
- Eroom's law: Scannell et al., Nat Rev Drug Discov 2012
- Software 2.0 framing: Karpathy, 2017
Frequently asked questions
What is Eroom's law and why does it matter to strategy?
Eroom's law is the decades-long fall in drug-discovery productivity despite rising investment: R&D spend has roughly doubled in ten years while output holds near ~50 drugs a year at under 10% success. It's the headwind any portfolio strategy has to beat.
What does 'data moat' actually mean here?
Your proprietary data, run through a self-improving loop, produces an advantage that widens with use - each experiment sharpens the next decision. Because the value is the compounding loop rather than one model, a competitor without your data and history can't easily catch up.
Was this built with Hydra?
No - like the monitoring work, it was a custom project for a partner on the PharosBio Clinical Trial Retriever API. That API is also available as a skill in Hydra, so the same early-stop and white-space analysis can be reproduced there.
Run this analysis on your question
Hydra plans, executes, and validates, so you reach a defensible answer in hours, not weeks.